Home / Guides /
Same medicines. Different questions.
GLP-1 for women: what the labels say about birth control, pregnancy, PCOS and menopause
By the NexLife Medical Team · Medically reviewed by Adam Kennah, MD · Updated
The 2026 labels say: back up birth control pills for 4 weeks after starting tirzepatide and each dose step; stop semaglutide 2 months before pregnancy. Women were 68% of SURMOUNT-1 (2022), Zepbound’s main weight trial, and 71% of Wegovy’s weight trials.
- The pill: back it up 4 weeks per tirzepatide dose step
- Planning a pregnancy? Stop semaglutide 2 months before trying
- Breastfeeding? Semaglutide tablets aren’t recommended
GLP-1 for women in brief: birth control, pregnancy, PCOS and menopause
- Birth control pills
- On tirzepatide, use a backup or non-oral method for 4 weeks after you start and after each dose increase
- Planning a pregnancy
- Stop semaglutide 2 months before; stop Zepbound once you’re pregnant
- Breastfeeding
- Not with semaglutide tablets or Foundayo; little tirzepatide reached milk in one small study
- PCOS or menopause
- Off-label: not FDA-approved uses; the weight-loss rules still apply
- Compounded medicines
- Not studied in these trials
Questions about the pill or pregnancy? Call or text
Compounded medicines aren’t FDA-approved. A NexLife provider prescribes one only if it offers a significant difference for you compared with an FDA-approved medicine.
The short version
Do GLP-1 s work for women? Quick answers on the pill and pregnancy
| Question | Answer |
|---|---|
| Do they work for women? | Women were most of the volunteers: 68% in SURMOUNT-1 (2022) and 71% in Wegovy’s weight trials. Weight fell regardless of sex, Zepbound’s label says. |
| Birth control pills? | On tirzepatide, switch to a non-oral method or add a barrier for 4 weeks after starting and each dose increase. Semaglutide’s labels show no such effect. |
| Planning a pregnancy? | Stop semaglutide at least 2 months before trying. Stop Zepbound once a pregnancy is recognized. |
| Hair loss? | Reported more by women in the labels’ trials: 7.1% vs 0.5% of men on Zepbound, and 4% vs 0.9% on Wegovy 2.4 mg. |
| Muscle? | Without strength training, muscle may be 10% to 15% of the weight women lose, a 2025 advisory estimates |
| Compounded versions? | Not FDA-approved, and not studied in these trials |
- Tell us about you About 3 minutes of health questions
- A licensed provider decides You’re prescribed only if it’s right for you
- Your partner pharmacy ships Usually within 1 to 2 business days, free
Key takeaways
- Tirzepatide and the pill: switch to a non-oral method, or add a barrier, for 4 weeks after starting and each dose increase, the Zepbound and Mounjaro labels say.
- Planning a pregnancy? Stop semaglutide at least 2 months before trying. Zepbound’s label says to stop once a pregnancy is recognized.
- Breastfeeding: semaglutide tablets and Foundayo aren’t recommended; for the shots, evidence is thin, so ask your provider.
- Women were most of the volunteers: 68% in SURMOUNT-1 (2022) and 71% in Wegovy’s weight trials.
- PCOS and menopause aren’t approved uses, so a
GLP-1 for them is off-label; the weight-loss rules still apply. - At NexLife, compounded tirzepatide is $115 a month and semaglutide $95 on the 12-month plan; neither is FDA-approved.
At a glance
Tirzepatide vs. semaglutide for women, at a glance
The facts from each label that matter most to women, side by side. Your provider decides which medicine, if any, fits you.
| Tirzepatide: Zepbound, Mounjaro | Semaglutide: Wegovy, Ozempic | |
|---|---|---|
| Made by | Eli Lilly | Novo Nordisk |
| FDA-approved foras of November 2026 | Zepbound: weight loss; moderate to severe sleep apnea with obesity. Mounjaro: type 2 diabetes; heart risk in type 2 diabetes | Wegovy: weight loss; heart risk with heart disease; MASH (pen). Ozempic: type 2 diabetes; heart risk in type 2 diabetes; kidney risk with the pen |
| How you take it | A weekly shot: single-dose pen, KwikPen or vial | Wegovy: a weekly pen or a daily pill. Ozempic: a weekly pen or a daily tablet (type 2 diabetes) |
| Dose rangelabel | 2.5 mg to start, then 5 to 15 mg a week | Wegovy pen 0.25 to 2.4 mg (7.2 mg for Wegovy HD); pill 1.5 to 25 mg a day. Ozempic pen 0.25 to 2 mg; Ozempic tablets 1.5 to 9 mg a day |
| Women in the main trials | 68% of 2,539 adults in SURMOUNT-1 (2022) | 71% of 2,116 adults on Wegovy in its three weight trials; 76% in the pill’s trial |
| Birth control pills | May work less well: switch to a non-oral method or add a barrier for 4 weeks after starting and after each dose increase | No clinically significant change in the pill’s hormones in label studies; oral medicines are monitored |
| Planning a pregnancy | Zepbound: stop once pregnant. No set stop time before trying; half-life about 5 to 6 days | Stop at least 2 months before trying (Wegovy and Ozempic labels) |
| Breastfeeding | Undetectable or low in milk in a small single-dose study; effects on babies unknown | Semaglutide tablets (Wegovy pill, Ozempic tablets, Rybelsus): not recommended. Shots: no data on milk |
| Hair losslabel, on the drug | Zepbound: 7.1% of women vs 0.5% of men | Wegovy 2.4 mg: 4% of women vs 0.9% of men |
| Nausealabel, drug vs placebo | Zepbound: 25% to 29% vs 8% | Wegovy 2.4 mg: 44% vs 16% |
| Self-pay, a monthchecked November 1, 2026 | Zepbound $299 to $449 at LillyDirect, by dose; $449 (from 7.5 mg) needs a refill within 45 days, or it’s $499 to $699. Mounjaro $499 | Wegovy pen $349 ($199 for each of a new patient’s first two fills through December 31, 2026); pill $149 to $299 at NovoCare |
| Medicare, 2026 to 2027 |
NexLife Price Match Guarantee†. Already on compounded tirzepatide or semaglutide with another licensed provider, and paying less? We match your regular monthly price. How it works
Swipe the table sideways to see every column.
From the prescribing information for Zepbound and Mounjaro (revised August 2026), Wegovy (June 2026), Ozempic (May 2026) and Ozempic tablets (January 2026), and prices from LillyDirect, NovoCare and Medicare.gov, all checked November 1, 2026. These trials studied FDA-approved Zepbound and Wegovy; compounded tirzepatide and semaglutide weren’t studied.
Your situation
Which GLP-1 fits your situation?
Start with what’s going on in your life right now. These are the label facts for each case; your provider makes the call.
If you take the pill
Tirzepatide and Foundayo carry the label warning: plan on a non-oral method or a barrier method after you start and after each dose step (4 weeks for tirzepatide, 30 days for Foundayo). Semaglutide’s labels show no such effect. Your provider decides which fits.
If a pregnancy is in your plans
Share your timeline first. Semaglutide has to stop at least 2 months before you try. Zepbound’s label sets no stop time before trying, but says to stop once you’re pregnant.
If you’re breastfeeding
Semaglutide tablets, including the Wegovy pill and Ozempic tablets, aren’t recommended, and neither is Foundayo. For tirzepatide, the labels weigh breastfeeding’s benefits against your need for the medicine, with little data either way. Your provider decides.
If you have PCOS
No
GLP-1 is approved for PCOS, so using one for it is off-label, and a weight-loss prescription rests on your BMI and health, as it would for anyone. If the pill is part of your PCOS care, the tirzepatide advice above applies.If you’re in perimenopause or menopause
The weight-loss approval doesn’t depend on menopause, but
GLP-1s aren’t approved for its symptoms. Muscle and bone loss risks rise now, so protein and strength work matter more.If you have type 2 diabetes
Mounjaro and Ozempic are the diabetes versions. Their labels allow use in pregnancy only if the benefit justifies the risk, and Mounjaro’s notes that poorly controlled diabetes carries risks of its own.
Trials
Do GLP-1s work as well for women?
As far as the trials show, yes: most volunteers were women, and weight fell whatever their sex. The labels don’t give separate averages for women and men.
| Trial | What it tested | Women |
|---|---|---|
| SURMOUNT-1published 2022 | Zepbound for weight, 72 weeks, 2,539 adults without diabetes | 68% |
| SURMOUNT-2published 2023; type 2 diabetes | Zepbound for weight, 72 weeks, 938 adults | 51% |
| Zepbound Studies 3 and 4after a lifestyle lead-in; keeping weight off | 579 and 670 adults randomized | 63% and 71% |
| SURMOUNT-OSApublished 2024 | Zepbound for sleep apnea, 52 weeks, 469 adults | 33% and 28% |
| Wegovy’s three weight trialspooled in the label | Wegovy 2.4 mg for up to 68 weeks, 2,116 adults on the drug | 71% |
| Wegovy 7.2 mg trialsWegovy HD | 1,311 adults on 7.2 mg | 70% |
| Wegovy pill trialtablets | Wegovy tablets for weight | 76% |
| Wegovy heart trialSELECT, published 2023 | Wegovy 2.4 mg or placebo in 17,604 adults with heart disease | 28% |
Swipe the table sideways to see every column.
Share of women enrolled, from the Zepbound label (revised August 2026, section 14; SURMOUNT-1 and SURMOUNT-2 are its Studies 1 and 2, SURMOUNT-OSA its Studies 5 and 6) and the Wegovy label (revised June 2026, sections 6.1 and 14.1). These trials studied FDA-approved Zepbound and Wegovy; compounded tirzepatide and semaglutide weren’t studied.
What the labels say about sex. In Zepbound’s weight trials, weight fell “irrespective of age, sex, race, ethnicity, baseline BMI, and glycemic status,” its label says. Neither label publishes an average for women alone. In SURMOUNT-1 (2022), where 2 in 3 volunteers were women, average loss at 72 weeks was 15.0% to 20.9% across the three doses, versus 3.1% on placebo.
Where results differ by sex. Hair loss was reported mostly by women (see below). And without structured strength training, muscle makes up 10% to 15% of the weight women lose, against 20% to 25% for men. That’s the estimate of a 2025 joint advisory from four medical and nutrition societies.
Birth control
Can you take birth control pills on a GLP-1?
Yes, but tirzepatide and Foundayo need a backup plan at the start and after each dose increase. Semaglutide’s labels show no such effect on the pill.
“may reduce the efficacy of oral hormonal contraceptives due to delayed gastric emptying”
When you start
Switch to a non-oral method, such as an IUD, implant, patch, ring or shot, or add a barrier method like condoms, for 4 weeks after your first dose.
Each time your dose goes up
Do it again for 4 weeks after every increase. The label raises the dose in 2.5 mg steps, at least 4 weeks apart.
On a steady dose
The label says the slowing of the stomach behind this is largest after the first dose and diminishes over time.
How big is the effect? In a label study, one 5 mg dose of tirzepatide cut peak blood levels of a combined pill’s hormones by 55% to 66%. Total exposure fell 20% to 23%, and the peak came 2.5 to 4.5 hours later (label section 12.3).
On Foundayo? Its label (revised July 2026) gives the same advice for 30 days after you start and after each dose increase. It also asks women who could become pregnant to use effective birth control while taking it. It isn’t recommended while breastfeeding, and it’s stopped once a pregnancy is recognized.
Semaglutide is different. The Wegovy and Ozempic labels list ethinyl estradiol and levonorgestrel, hormones in many combined pills, among drugs with no clinically significant change alongside semaglutide. Both still ask for care with oral medicines, since semaglutide slows the stomach too.
On the Wegovy pill or Ozempic tablets? Their labels (Wegovy, Ozempic tablets) say to take the tablet on an empty stomach with up to 4 ounces of water, then wait at least 30 minutes before food, drinks or other pills, birth control included.
From the Zepbound and Mounjaro prescribing information (revised August 2026), sections 7.2, 8.3 and 12.3; the Foundayo label (July 2026), sections 7.3 and 8.1 to 8.3; and the Wegovy (June 2026), Ozempic (May 2026) and Ozempic tablets (January 2026) labels, sections 2, 7.2 and 12.3. Compounded tirzepatide wasn’t studied; ask your provider how the label advice applies to you.
Pregnancy
When should you stop a GLP-1 before pregnancy?
Semaglutide needs at least 2 months. Zepbound’s label sets no stop time before you try, but says to stop once you’re pregnant, since weight loss offers no benefit then.
| Medicine | Planning a pregnancy | Once you’re pregnant |
|---|---|---|
| Zepboundtirzepatide, weight loss | No set stop time in the label. Tirzepatide’s half-life is about 5 to 6 days | Stop. Weight loss offers no benefit and may cause fetal harm, the label says |
| Mounjarotirzepatide, type 2 diabetes | No set stop time in the label | Use only if the potential benefit justifies the potential risk to the fetus |
| Wegovysemaglutide, pen or pill | Stop at least 2 months before. Semaglutide stays in the blood 5 to 7 weeks | Stop, whether you take it for weight loss or heart risk; for MASH, only if the benefit justifies the risk |
| Ozempicsemaglutide, type 2 diabetes: pen or tablets | Stop at least 2 months before | Use only if the potential benefit justifies the potential risk to the fetus |
| Foundayoorforglipron, a daily pill for weight loss | No set stop time in the label; it asks for effective birth control while you take it | Stop once a pregnancy is recognized |
Swipe the table sideways to see every column.
From each prescribing information, sections 8.1, 8.3 and 12.3 (Zepbound and Mounjaro revised August 2026, Foundayo July 2026, Wegovy June 2026, Ozempic May 2026, Ozempic tablets January 2026), checked November 1, 2026. Your provider decides your timing. Compounded versions weren’t studied in pregnancy.
Why the labels are careful. There are too few data from pregnant women to show a risk or rule one out. In animal studies at exposures like those in people, tirzepatide caused reduced fetal growth and fetal abnormalities in rats, and reduced fetal growth in rabbits. These effects came with the mothers eating less and losing weight. Wegovy’s label says semaglutide may pose risks to the fetus too.
Gaining weight in pregnancy is expected. Zepbound’s label says appropriate weight gain, based on weight before pregnancy, is recommended for every pregnant patient, including those with obesity.
Pregnant now? Tell your provider right away. The labels list registries for pregnancies exposed to Zepbound (Lilly, 1-844-524-0039) and to Wegovy (Novo Nordisk, 1-877-390-2760).
Breastfeeding
Can you breastfeed on a GLP-1?
Not on semaglutide tablets (the Wegovy pill, Ozempic tablets or Rybelsus) or Foundayo, their labels say. For the shots, the evidence is thin, so you and your provider weigh it.
Tirzepatide: Zepbound, Mounjaro
In a label study of 11 breastfeeding women given one 5 mg dose, tirzepatide was undetectable in 164 of 171 milk samples. Effects on babies and on milk supply haven’t been studied.
Semaglutide tablets: Wegovy pill, Ozempic tablets, Rybelsus
Breastfeeding isn’t recommended. The tablets contain SNAC, an ingredient that helps absorption, and it passes into breast milk.
Semaglutide shots: Wegovy and Ozempic pens
There are no data on semaglutide in human milk. The pens don’t contain SNAC.
Foundayo, Lilly’s daily pill
Breastfeeding isn’t recommended while you take it, its label (revised July 2026) says.
Weighing it. For tirzepatide, the labels say to consider breastfeeding’s benefits for your baby’s development and health alongside your own need for the medicine and any possible effect on the baby. That’s a decision to make with your provider.
From the Zepbound and Mounjaro (August 2026), Foundayo (July 2026) and Wegovy (June 2026) prescribing information, section 8.2, and the Ozempic (May 2026) and Rybelsus and Ozempic tablets (January 2026) labels. Compounded tirzepatide and semaglutide weren’t studied in breastfeeding.
Menopause
Do GLP-1s help with menopause weight gain?
They’re approved for weight loss whatever your menopause status, but not for menopause or its symptoms, such as hot flashes.
Who qualifies. Zepbound and Wegovy are approved for adults with obesity, or with overweight and at least one weight-related condition. In SURMOUNT-1 that meant a BMI of 30 or more, or 27 to under 30 with a condition such as high blood pressure, abnormal cholesterol, sleep apnea or heart disease. More: tirzepatide BMI requirements.
Not approved for menopause itself. No
Taking hormone therapy? Neither label names menopausal hormone therapy. Zepbound’s asks for caution with oral medicines in general, because tirzepatide slows the stomach; its specific advice covers birth control pills only. Give your provider a full list, patches and gels included.
Muscle and bone matter more now. The 2025 advisory lists perimenopause and menopause among the risk factors for muscle loss and for eating too little protein. Its bone figures are below.
PCOS
Can tirzepatide or semaglutide help with PCOS?
They may help with weight, but using a
- 54,114women prescribed tirzepatide through a UK online weight service, February 2024 to January 20254,241 reported PCOS (J Endocr Soc, 2026)
- 19.4% vs 18.7%average weight loss at 10 months, with and without PCOSno significant difference (Clift and colleagues, J Endocr Soc, 2026)
- 40women with PCOS still in the data at 10 monthsaverage follow-up was about 2 months (J Endocr Soc, 2026)
The study’s limits. PCOS and weight were self-reported. The service didn’t routinely record reproductive or hormone measures, such as ovulation or androgen levels. And four of the five authors work for the company that ran it (Clift and colleagues, Journal of the Endocrine Society, 2026). The study didn’t include compounded tirzepatide.
Trials are testing it directly. ClinicalTrials.gov lists a study of tirzepatide’s effects on reproductive function and metabolic health in women with PCOS and overweight or obesity (NCT07326111). In the UK, a randomized trial called SEMMET was set up to compare semaglutide with metformin in women with PCOS and obesity. Its sponsor is Hull University Teaching Hospitals, and it was given ethics approval in May 2022.
On the pill for PCOS? The tirzepatide label’s 4-week backup advice applies, because it covers anyone using oral hormonal contraceptives.
Coverage. PCOS isn’t an approved use, so using a
Muscle and bone
Do GLP-1s cause muscle and bone loss in women?
Some of the weight lost is lean mass, and large, fast loss can thin bone. Protein and strength training help protect muscle, and slower loss may spare bone, a 2025 advisory says.
- 38%of the weight lost in STEP 1 (Wegovy, 2021) was lean massabout 20% was muscle, the advisory estimates
- 10–15%of the weight women lose may be musclewithout structured strength training (modeling, 2025 advisory)
- 1.2–1.6 gprotein per kg of body weight a day, proposed during weight lossor 80 to 120 g a day (2025 advisory)
Protein isn’t enough on its own. The advisory says extra protein alone is likely inadequate to preserve muscle without structured resistance or strength training. It also suggests considering supplements for nutrients that can run low, such as vitamin D and calcium. Meal ideas: what to eat on a
Bone. Weight loss that is large and fast, 14% or more over 3 to 4 months, is tied to significant bone loss, the advisory notes. Women and older adults lose more bone. Slower, more moderate loss may better preserve bone.
Hair: more common in women
In Zepbound’s trials, 7.1% of women reported hair loss, versus 0.5% of men (1.3% and none on placebo). On Wegovy 2.4 mg it was 4% of women and 0.9% of men, and Wegovy’s label ties it to weight reduction. Why it happens and what helps: tirzepatide hair loss. These trials studied FDA-approved Zepbound and Wegovy; compounded tirzepatide and semaglutide weren’t studied.
In their words
What do the labels say about GLP-1s for women?
Hair loss is one result that differed by sex in Zepbound’s trials:
“hair loss was reported more frequently in female than male patients in the ZEPBOUND (7.1% female versus 0.5% male) and placebo (1.3% female versus 0% male) treatment groups.”
Eli Lilly and Company, Zepbound (tirzepatide) prescribing information, revised February 2026 (FDA’s copy)
The approval doesn’t depend on menopause; Wegovy’s label, like Zepbound’s, says who it’s for by weight and health:
“To reduce excess body weight and maintain weight reduction long term in adults with obesity, or in adults with overweight in the presence of at least one weight-related comorbid condition.”
Novo Nordisk, Wegovy (semaglutide) prescribing information, section 1, revised June 2026
Safety
Who shouldn’t take a GLP-1, and when should you call a doctor?
Most side effects are stomach-related. These are the people the labels rule out, and the signs that need a call or emergency care.
Boxed warning: thyroid C-cell tumors. Tirzepatide and semaglutide caused thyroid C-cell tumors in rodents; it isn’t known whether they do in people. Don’t take either if you or a family member has had medullary thyroid carcinoma (MTC), or if you have multiple endocrine neoplasia syndrome type 2 (MEN 2). They’re also off the table after a serious allergic reaction to the medicine or its ingredients. Zepbound’s label also says it isn’t recommended for people with severe gastroparesis, a stomach that empties very slowly.
Get emergency help for swelling of your face, lips, tongue or throat, or trouble breathing or swallowing: stop the medicine and call 911.
| Warning sign | What it can mean | What to do |
|---|---|---|
| Stomach pain that’s severe or won’t let upsometimes spreading to your back | Pancreatitis | Stop the medicine and call your provider right away |
| Upper stomach pain, fever, yellowing skin or eyes, or pale stools | Gallbladder disease, such as gallstones | Call your provider |
| Vomiting or diarrhea that keeps going | Dehydration, which can injure the kidneys | Sip fluids and call your provider |
| Shaking, sweating, confusion or a racing heartmore likely with insulin or a sulfonylurea | Low blood sugar | Treat it the way your provider showed you, then tell them |
| A lump in your neck, hoarseness or trouble swallowing | A possible thyroid tumor | Tell your provider |
| Blurry or changing visionwith type 2 diabetes | Diabetic eye disease getting worse | Tell your provider |
Swipe the table sideways to see every column.
From the Zepbound prescribing information (revised August 2026), boxed warning and sections 4 and 5, and the Wegovy label (June 2026). If your provider tells you something different, follow your provider.
Surgery or a procedure with anesthesia coming up? Tell everyone treating you that you take a
Step by step
How do you get ready to start a GLP-1?
Six checks for women, from the labels and a 2025 advisory. Your provider makes the call.
- Share your plans. Tell your provider if you could become pregnant, are planning a pregnancy or are breastfeeding. Your plans change which medicine fits.
- Check your birth control. On tirzepatide and the pill, switch to a non-oral method, or add a barrier method such as condoms. Do it for 4 weeks after you start and after each dose increase.
- Time a pregnancy. Stop semaglutide at least 2 months before you try. Zepbound’s label says to stop once a pregnancy is recognized.
- Ask about breastfeeding. Semaglutide tablets and Foundayo aren’t recommended. For the shots, the evidence is thin, so you and your provider weigh it.
- Protect muscle and bone. A 2025 advisory proposes 80 to 120 g of protein a day, with strength training. Have kidney disease? Ask your provider first.
- Know the warning signs. For stomach pain that’s severe or won’t let up, stop the medicine and call your provider right away.
The six steps above, in order. The labels and your provider’s advice come first.
Vial math
How many units is your tirzepatide dose?
It depends on your vial’s strength. Here are the label’s doses at one example strength. On the pill, each step up means another 4 weeks with a non-oral or barrier method.
| Dose | mL at 25 mg/mL | Units (U-100) | On the pill |
|---|---|---|---|
| 2.5 mgto start | 0.1 mL | 10 units | 4 weeks of backup after your first dose |
| 5 mg | 0.2 mL | 20 units | 4 weeks of backup after this increase |
| 7.5 mg | 0.3 mL | 30 units | 4 weeks of backup after this increase |
| 10 mg | 0.4 mL | 40 units | 4 weeks of backup after this increase |
| 12.5 mg | 0.5 mL | 50 units | 4 weeks of backup after this increase |
| 15 mgthe maximum | 0.6 mL | 60 units | 4 weeks of backup after this increase |
The math: mL = dose ÷ strength (mg per mL), and units = mL × 100. At 25 mg/mL, 5 mg is 5 ÷ 25 = 0.2 mL, or 20 units. 25 mg per mL is an example only: it’s the strength of the 15 mg multi-dose vial on Zepbound’s label (15 mg per 0.6 mL). Zepbound’s multi-dose vials come in a strength for each dose, 0.6 mL a dose, so read the strength on your own vial’s label. Your provider sets your dose. Every step: the tirzepatide dosage chart. Or enter your own vial’s strength in the tirzepatide dosage calculator. On semaglutide? Use the semaglutide dosage chart.
Cost
Is a GLP-1 for PCOS or menopause covered, and what does it cost?
Neither PCOS nor menopause is an approved use, so using a
| How you pay | A month | A year, or good to know |
|---|---|---|
| Commercial insurance that covers itwith the maker’s savings card | As little as $25, with up to $100 off a month | Lilly’s Zepbound cards end December 31, 2026; Medicare and Medicaid are excluded |
| Zepbound, LillyDirectKwikPen or vials; refill within 45 days | $299 at 2.5 mg, $399 at 5 mg, $449 from 7.5 mg; $499 to $699 without the 45-day refill | $5,837 for 13 four-week fills at $449 |
| Mounjaro, LillyDirecttype 2 diabetes | $499 at every dose | Self-pay; Lilly’s terms apply |
| Wegovy pen, NovoCareself-pay | $349, or $399 for Wegovy HD; $199 for each of a new patient’s first two fills through December 31, 2026 | $4,537 for 13 fills at $349 |
| Wegovy pill, NovoCare30 tablets | $149 at 1.5 mg, $199 at 4 mg, $299 at 9 or 25 mg | $3,588 at $299, the 25 mg maintenance dose |
| Foundayo pill, LillyDirectorforglipron | $149 to $299 by dose (14.5 and 17.2 mg with a refill within 45 days); 2.5 and 5.5 mg are reduced through December 31, 2026 | $3,588 at $299, the 9 to 17.2 mg doses |
| TrumpRx.gova government price listing | The makers’ self-pay prices: Zepbound starting at $299; Wegovy pen $349, or $199 for each of a new patient’s first two fills through December 31, 2026 | Self-pay prices; Wegovy’s coupon can’t be billed to insurance or counted toward a deductible |
| Medicare | $50 for the Zepbound KwikPen, Wegovy or Foundayo | Through December 31, 2027; doesn’t count toward your out-of-pocket limit |
| Compounded tirzepatide at NexLifeisn’t FDA-approved | $115 on the 12-month plan, or $129 month to month, every dose | $1,380 on the 12-month plan; $1,548 month to month |
| Compounded semaglutide at NexLifeisn’t FDA-approved | $95 on the 12-month plan, or $109 month to month, every dose | $1,140 on the 12-month plan; $1,308 month to month |
NexLife Price Match Guarantee†. Already on compounded tirzepatide or semaglutide with another licensed provider, and paying less? We match your regular monthly price. How it works
Swipe the table sideways to see every column.
Self-pay prices from LillyDirect, NovoCare (wegovy.com) and TrumpRx.gov; Medicare from Medicare.gov and CMS; all checked November 1, 2026. A Zepbound or Wegovy pen month is 28 days. The makers’ savings cards need commercial coverage of the medicine. Compounded prices are all in, at every dose, and compounded medicines are different products from the brands.
The yearly gap. At LillyDirect’s $449 from 7.5 mg, which needs a refill within 45 days (or it’s $499 to $699), a year of Zepbound is $5,837. On NexLife’s 12-month plan, a year of compounded tirzepatide is $1,380, or $1,548 month to month. They’re different products: compounded tirzepatide isn’t FDA-approved and isn’t Zepbound. More: compounded vs. brand-name tirzepatide.
Have type 2 diabetes? NexLife’s providers prescribe compounded tirzepatide and semaglutide for weight loss. They aren’t a treatment for type 2 diabetes and don’t replace Mounjaro, Ozempic or your diabetes care.
On Medicare? The Bridge needs a BMI of 35 or more, or a lower BMI with certain conditions. It leaves out people with type 2 diabetes, moderate to severe sleep apnea or fatty liver disease; their Part D plan may cover a
Paying less for compounded tirzepatide or semaglutide elsewhere? NexLife’s Price Match Guarantee† matches your regular monthly price with another licensed provider, for as long as your plan stays active.
At NexLife
GLP-1 care at NexLife: what’s included and what it costs
Here’s what you get if a NexLife provider prescribes compounded tirzepatide or semaglutide for you.
Care from a licensed provider
A provider licensed in your state reviews your health history online and prescribes only if treatment is right for you. Not prescribed? No charge for medication.
One price at every dose
Compounded tirzepatide is $115 a month on the 12-month plan, $119 on 6 months, $125 on 3 months or $129 month to month. Compounded semaglutide is $95 a month on the 12-month plan, $99 on 6 months, $105 on 3 months or $109 month to month. No membership fee. Compounded tirzepatide and semaglutide aren’t FDA-approved and aren’t Zepbound or Wegovy; a licensed provider prescribes them only when they offer a significant difference for you.
Price Match Guarantee†
Already on compounded tirzepatide or semaglutide with another licensed provider? Send a receipt from the last 60 days, and we match your regular monthly price for as long as your plan stays active.
Two named pharmacies
Absolute Pharmacy in Lutz, FL, or Boudreaux’s New Drug Store in Lake Charles, LA, both state-licensed 503A pharmacies, fills your prescription. NexLife works only with pharmacies licensed in the states they ship to, and questions about your order come to us, not to them.
Support between refills
A nutrition plan, a 1:1 coaching call and real people at
(949) 818-8000 , by call or text, 24/7. Physicians answer medical questions during clinical hours.Paying and shipping
Affirm, Klarna or Afterpay at checkout, or an HSA or FSA card, with a letter of medical necessity from NexLife. Shipping is free and expedited; your partner pharmacy usually ships within 1 to 2 business days.
NexLife is rated 4.8 out of 5 on Trustpilot from 407 reviews (read November 1, 2026) and is LegitScript-certified.
What does NexLife cost?
One flat price at every dose.
No membership fee. Provider care, a nutrition plan, coaching and shipping are included. Paying less with another licensed provider? We match your regular monthly price.†
GIP + 12-month plan $115/mo
Tirzepatide
Weekly and dual-action. Care, coaching and shipping included. On a 12-month plan; $129/mo month to month.
Check my eligibilityCompounded, not FDA-approved · Not prescribed? No charge for medication

12-month plan $95/mo
Semaglutide
Weekly
Compounded, not FDA-approved · Not prescribed? No charge for medication
Compounded, not FDA-approved. A licensed provider prescribes it only when it offers a significant difference for you. Vials shown are illustrations. Always use the strength on your pharmacy’s label. Every plan and price · Price Match Guarantee† terms
The NexLife Price Match Guarantee†
Paying less elsewhere?
Keep your price. Upgrade your care.
Already on compounded tirzepatide or semaglutide? Pay less with another licensed U.S. telehealth provider or clinic, and we match your regular monthly price for as long as your plan stays active.† Plus a provider who follows your dose, a nutrition plan, a coaching call and real people 24/7.
- 1Send a receipt from the last 60 days
- 2A NexLife provider reviews your prescription
- 3Pay your matched price, at every dose
Locked while your plan is activeSame price at every doseNo membership fee
†Terms: see the Price Match Guarantee† details below. Compounded medications aren’t FDA-approved; a provider prescribes one only when it offers a significant difference for you.
GLP-1s for women: your questions
Fair questions about NexLife
- Will my price go up with my dose?
- No. You pay the same at every dose.
- What if I’m not prescribed?
- You aren’t charged for medication.
- Can I cancel?
- Yes, by email. It takes effect 30 days after we receive it. Plans renew until you cancel; our cancellation policy has the details.
- Do I need insurance?
- No. Pay with an HSA or FSA card, or with Affirm, Klarna or Afterpay at checkout.
Can women on tirzepatide keep taking birth control pills?
Yes, with a backup plan. The Zepbound and Mounjaro labels say to switch to a non-oral method, or add a barrier method such as condoms, for 4 weeks after your first dose and after each dose increase. Hormonal birth control not taken by mouth, such as a patch, ring, shot, implant or hormonal IUD, shouldn’t be affected, they say.
Do Wegovy and Ozempic make birth control pills less effective for women?
Their labels don’t say so. In label studies, ethinyl estradiol and levonorgestrel, the hormones in many combined pills, showed no clinically significant change with semaglutide. The labels still advise care with oral medicines, because semaglutide slows the stomach, and semaglutide tablets need a 30-minute gap before other pills.
How long before trying to get pregnant should women stop a GLP-1?
For semaglutide, at least 2 months: the Wegovy and Ozempic labels say so because it stays in the body for weeks. Zepbound’s label sets no stop time before you try, and says to stop once you’re pregnant; tirzepatide’s half-life is about 5 to 6 days. Your provider decides your timing.
What should a woman do if she gets pregnant on a GLP-1?
Tell your provider right away. Zepbound’s label says to stop it when a pregnancy is recognized, and Wegovy’s says to stop it if you take it for weight loss or heart risk. Mounjaro and Ozempic are used only if the benefit justifies the risk. Pregnancy registries: Zepbound’s at 1-844-524-0039, Wegovy’s at 1-877-390-2760.
Can women breastfeed while taking a GLP-1?
It depends on the medicine. Semaglutide tablets (the Wegovy pill, Ozempic tablets and Rybelsus) aren’t recommended while breastfeeding, because an ingredient that helps absorption passes into milk. In a small single-dose study, tirzepatide was undetectable or low in milk, and there are no milk data for the semaglutide shots. Your provider helps you weigh it.
Do GLP-1s help women lose weight during menopause?
They’re approved for weight loss whatever your menopause status: Zepbound and Wegovy are for adults with obesity, or overweight with a weight-related condition. Neither is approved for menopause itself or for hot flashes. Because muscle and bone loss risks rise then, protein and strength training matter more.
How much protein do women need on a GLP-1?
A 2025 advisory from four medical and nutrition societies proposes 1.2 to 1.6 g of protein per kg of body weight a day during weight loss, or 80 to 120 g a day. It adds that protein alone likely won’t preserve muscle without structured strength training. Have kidney disease? Ask your provider before you eat more protein.
Is any GLP-1 approved for PCOS in women?
No, so using one for PCOS is off-label. In a 2026 study of 54,114 women prescribed tirzepatide online in the UK, those reporting PCOS lost about as much weight at 10 months as those without it, but only 40 with PCOS were still followed by then. Compounded tirzepatide wasn’t studied.
What do the GLP-1 trials show for women?
Women were 68% of Zepbound’s main weight trial and 71% of Wegovy’s weight trials; the 2026 labels set rules on the pill, pregnancy and breastfeeding. Zepbound’s label says weight fell regardless of sex, but neither label gives a separate average for women. Compounded tirzepatide and semaglutide weren’t studied in these trials.
Does Foundayo make birth control pills less effective?
Its label carries the same kind of warning as tirzepatide’s: plan on a non-oral or barrier method for 30 days after you start and after each dose increase. It also asks women who could become pregnant to use effective birth control, and it isn’t recommended while breastfeeding.
Is hair loss on GLP-1 s more common in women?
Yes, in the label trials. On Zepbound, 7.1% of women reported hair loss, versus 0.5% of men (1.3% and none on placebo). On Wegovy 2.4 mg it was 4% of women and 0.9% of men, and Wegovy’s label ties it to weight reduction. Compounded versions weren’t studied.
Can you take a GLP-1 with menopause hormone therapy?
Neither the Zepbound nor the Wegovy label names menopausal hormone therapy. Zepbound’s asks for caution with oral medicines in general, because tirzepatide slows the stomach; its specific advice covers birth control pills only. Give your provider a full list of what you take, patches and gels included.
Important safety information
Compounded tirzepatide and semaglutide are not FDA-approved, and the FDA hasn’t reviewed them for safety, effectiveness or quality. A provider prescribes them only when they offer a significant difference for you compared with an FDA-approved product. Both medicines may cause thyroid tumors, including cancer: don’t use either if you or a family member has had medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2).
Read the full safety information
In studies with rodents, both medicines caused thyroid tumors; it isn’t known whether they cause them in people. Tell your provider if you notice a lump or swelling in your neck, hoarseness, trouble swallowing or shortness of breath. Serious side effects can include inflammation of the pancreas (pancreatitis), gallbladder problems, low blood sugar (especially with insulin or sulfonylureas), kidney problems from dehydration, severe stomach problems, serious allergic reactions, vision changes in people with type 2 diabetes, and a faster heart rate. The FDA warned on Nov. 9, 2026, that GLP-1 medicines may raise the risk of NAION, a rare eye condition that can cause sudden vision loss in one eye; call your provider right away if that happens (FDA). Tell your care team before any surgery or procedure that uses anesthesia or deep sedation. Don’t combine either medicine with other
Tirzepatide can make birth control pills less effective: switch to a non-oral method, or add a barrier method such as condoms, for 4 weeks after you start and for 4 weeks after each dose increase. Both medicines may harm an unborn baby. Semaglutide should be stopped at least 2 months before a planned pregnancy. Tell your provider right away if you’re pregnant, planning to be, or breastfeeding.
This is a summary, not the complete safety information. Read the full Prescribing Information for FDA-approved tirzepatide (Zepbound) and semaglutide (Wegovy), and talk with your provider. You can report side effects to the FDA at
† NexLife Price Match Guarantee: for new NexLife members switching from a licensed U.S. telehealth provider or clinic with an active prescription for compounded tirzepatide or semaglutide. We match your regular all-in monthly price there (medication plus any required membership, program or visit fee, on a month-to-month plan); first-month offers, coupons, referral credits and prepaid multi-month rates aren’t matched. Proof from the last 60 days required. A licensed provider must determine that treatment is right for you. Not open to people with Medicare, Medicaid or TRICARE coverage. Full terms.
About NexLife. NexLife is a telehealth and care-coordination platform. Care is delivered through affiliated, physician-owned medical groups, and licensed providers decide whether treatment is right for you. NexLife doesn’t make or compound medication: state-licensed partner pharmacies fill each prescription, and we coordinate the rest. Available only in states where our affiliated providers are licensed.
Who wrote and medically reviewed this page?
Leads the NexLife Medical Team, which writes and medically reviews NexLife’s guides, including this one.
Checked every clinical fact against its label and every price at its seller on November 1, 2026.
- How we checked. Every clinical fact here comes from the prescribing information for Zepbound and Mounjaro (revised August 2026), Foundayo (July 2026), Wegovy (June 2026), Ozempic (May 2026) and Rybelsus and Ozempic tablets (January 2026), read on November 1, 2026, or from the study named beside it. Prices come from LillyDirect, NovoCare, TrumpRx.gov, CMS and Medicare.gov, checked the same day. We don’t give dosing plans: your provider decides. Zepbound, Mounjaro and Foundayo are trademarks of Eli Lilly and Company; Ozempic, Wegovy and Rybelsus of Novo Nordisk. NexLife isn’t affiliated with either.
- Every fact, sourced. Each price and rule links to the page it comes from.
- How we make money. NexLife is a telehealth and care-coordination platform. We earn revenue when people join NexLife.
- Corrections, fast. See something wrong or out of date? Email hello@nexlife.us and we’ll fix it.
- How we work. How we review programs · GLP-1 price index · Is NexLife legit? · States NexLife serves
Paying less elsewhere? We match it.†
You know what the labels say. Next: a 3-minute check.
A licensed provider reviews your health history and decides if compounded tirzepatide or semaglutide is right for you. $115 a month on the 12-month plan, or $129 month to month, at every dose.
4.8 out of 5 on Trustpilot, 407 reviews (read Nov. 1, 2026) · Medical director Adam Kennah, MD (NPI 1144260043) · LegitScript-certified
Compounded medications aren’t FDA-approved. A provider prescribes one only when it offers a significant difference for you.
- 1Tell us about you
Start online with your health history.
- 2A licensed provider decides
Online, following your state’s rules. You’re prescribed only if treatment is right for you.
- 3We ship it, then stay with you
Our partner pharmacy usually ships within 1 to 2 business days. Free shipping, and questions come to us 24/7, never to the pharmacy.
Sources
- Zepbound (tirzepatide) prescribing information, Eli Lilly (revised August 2026). Read November 1, 2026.
- Zepbound (tirzepatide) prescribing information, revised August 2026, on DailyMed (National Library of Medicine). Read Nov. 12, 2026.
- Mounjaro (tirzepatide) prescribing information, Eli Lilly (revised August 2026). Read November 1, 2026.
- Mounjaro (tirzepatide) prescribing information, FDA copy (revised January 2026; contraception, pregnancy and lactation sections). Read Nov. 12, 2026.
- Wegovy (semaglutide) injection and tablets prescribing information, Novo Nordisk (revised June 2026). Read November 1, 2026.
- Wegovy (semaglutide) prescribing information, FDA copy (revised June 2026). Read Nov. 12, 2026.
- Ozempic (semaglutide) prescribing information, Novo Nordisk (revised May 2026). Read November 1, 2026.
- Ozempic (semaglutide) prescribing information, FDA copy (revised May 2026). Read Nov. 12, 2026.
- Rybelsus and Ozempic (semaglutide) tablets prescribing information, Novo Nordisk (revised January 2026). Read November 1, 2026.
- Rybelsus and Ozempic (semaglutide) tablets prescribing information, FDA copy (revised January 2026). Read Nov. 12, 2026.
- Foundayo (orforglipron) prescribing information, Eli Lilly (revised July 2026). Read November 1, 2026.
- Foundayo (orforglipron) prescribing information, FDA copy (revised July 2026). Read Nov. 12, 2026.
- American Academy of Sleep Medicine: Zepbound provider fact sheet (SURMOUNT-OSA, N Engl J Med 2024;391:1193-1205). Read November 1, 2026.
- SURMOUNT-2: Garvey WT, et al. The Lancet 2023;402:613-26. Citation checked October 25, 2026.
- Mozaffarian D, et al. Nutritional priorities to support
GLP-1 therapy for obesity: a joint advisory. Obesity, 2025;33(8):1475-1503. Read Nov. 12, 2026. - Clift AK, et al. Weight loss outcomes with tirzepatide in women with and without self-reported polycystic ovary syndrome. J Endocr Soc, 2026;10(9):bvag177. Read Nov. 12, 2026.
- ClinicalTrials.gov: NCT07326111, tirzepatide and reproductive function in women with PCOS. Listing checked October 25, 2026.
- Health Research Authority: semaglutide vs metformin in polycystic ovary syndrome (SEMMET), research summary. Read November 1, 2026.
- LillyDirect: Zepbound self-pay prices. Checked November 1, 2026.
- LillyDirect: Mounjaro self-pay prices. Checked November 1, 2026.
- LillyDirect: Foundayo self-pay prices. Checked November 1, 2026.
- Eli Lilly: Zepbound savings card and self-pay terms. Read November 1, 2026.
- Novo Nordisk: What to pay for Wegovy. Checked November 1, 2026.
- TrumpRx.gov: Zepbound. Checked November 1, 2026.
- TrumpRx.gov: Wegovy pen. Checked November 1, 2026.
- CMS: Medicare
GLP-1 Bridge. Read November 1, 2026. - Medicare.gov: Weight loss drugs (who qualifies for the Bridge). Read Nov. 12, 2026.
- Novo Nordisk: US list price reduction for Wegovy, Ozempic and Rybelsus (February 24, 2026). Read November 1, 2026.
- NexLife: pricing, every plan.
- Zepbound (tirzepatide) prescribing information, Eli Lilly (revised February 2026), FDA’s copy.